Press release
Overactive Bladder Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Dong-A ST Co., AbbVie, Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics
"Overactive Bladder Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Overactive Bladder Therapeutics Market.
The report provides a detailed description of the Overactive Bladder drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Overactive Bladder Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Overactive Bladder Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Overactive Bladder therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Overactive Bladder drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Overactive Bladder treatment market.
Learn More about the Clinical and Commercial Development Activities in the Overactive Bladder Therapeutics Domain @
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Overactive Bladder Therapeutics Analysis
There are approx. 15+key companies developing therapies for Overactive Bladder. Currently, Deerland Probiotics & Enzymes is leading the therapeutics market with its Overactive Bladder drug candidates in the most advanced stage of clinical development.
Overactive Bladder Companies in the Therapeutics Market Include:
• Dong-A ST Co., Ltd.
• AbbVie
• Medytox
• Urovant Sciences
• Taiho Pharma
• Velicept Therapeutics
And Many Others
Emerging and Marketed Overactive Bladder Therapies Covered in the Report Include:
• Neuronox: AbbVie/Medytox
• URO-902: Urovant Sciences
And Many More
Get an in-depth Assessment of the Emerging Therapies and Overactive Bladder Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Overactive Bladder Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Overactive Bladder Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Overactive Bladder Current Treatment Patterns
4. Overactive Bladder - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Overactive Bladder Late-Stage Products (Phase-III)
7. Overactive Bladder Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Overactive Bladder Discontinued Products
13. Overactive Bladder Product Profiles
14. Overactive Bladder Companies
15. Overactive Bladder Drugs
16. Dormant and Discontinued Products
17. Overactive Bladder Unmet Needs
18. Overactive Bladder Future Perspectives
19. Overactive Bladder Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Overactive Bladder Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Dong-A ST Co., AbbVie, Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics here
News-ID: 3325223 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Overactive
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Top Factor Driving Overactive Bladder Treatment Market Growth in 2025: Geriatric …
What industry-specific factors are fueling the growth of the overactive bladder treatment market?
The anticipated growth of the overactive bladder treatment market is largely attributed to an increasing geriatric population. This term pertains to individuals who are 65 years old and above. The susceptibility of geriatric patients to urinary tract infections is higher due to multiple factors like reduced urine flow, overactive bladder, enlarged prostate or presence of kidney stones, thereby…
Overactive Bladder Market - Empowering Life Without Limits: Overactive Bladder S …
Newark, New Castle, USA - new report, titled Overactive Bladder Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Overactive Bladder market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Overactive Bladder market. The report offers an overview of the market, which…
Overactive Bladder Market Report, History and Forecast 2022-2030
Overactive Bladder Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Overactive Bladder industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
Overactive Bladder Treatment Market by Drug Type (Anticholinergics, Mirabegron, …
Market Analysis and Insights of Overactive Bladder Treatment Market
During the forecasted period of 2023-2032, the market for treatments for overactive bladder will grow at a CAGR of about 4.00%. The main drivers of the overactive bladder treatment market's expansion are the rising prevalence of kidney-related disorders, increased emphasis on medical device research and development expertise and the adoption of cutting-edge IT healthcare technologies, an increasing geriatric population worldwide, and rising…
